Search

Your search keyword '"Creutzberg, C L"' showing total 124 results
Start Over Author "Creutzberg, C L"
124 results on '"Creutzberg, C L"'

1. Tumoren van de vrouwelijke geslachtsorganen

Author

Bekkers, R. L. M., Creutzberg, C. L., Witteveen, P. O., Vergeldt, T. F. M., Smedts, F., Slangen, B. F. M., van Krieken, J.H.J.M., editor, Beets-Tan, R.G.H., editor, Gelderblom, A.J., editor, Olofsen, M.J.J., editor, and Rutten, H.J.T., editor

Published
2020
Full Text
View/download PDF

2. Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity substudy

Author

Suvaal, I., Kirchheiner, K., Nout, R. A., Sturdza, A. E., Van Limbergen, E., Lindegaard, J. C., Putter, H., Jürgenliemk-Schulz, I. M., Chargari, C., Tanderup, K., Pötter, R., Creutzberg, C. L., ter Kuile, M. M., and Radiotherapy

Subjects
Adaptive radiotherapy, Oncology, SDG 3 - Good Health and Well-being, Brachytherapy, Cervical cancer, Obstetrics and Gynecology, Vaginal changes, Sexual distress, Sexual functioning
Abstract

Objective: The EMBRACE-vaginal morbidity substudy prospectively evaluated physician-assessed vaginal changes and patient-reported-outcomes (PRO) on vaginal and sexual functioning problems and distress in the first 2-years after image-guided radio(chemo)therapy and brachytherapy for locally advanced cervical cancer. Methods: Eligible patients had stage IB1-IIIB cervical cancer with ≤5 mm vaginal involvement. Assessment of vaginal changes was graded using CTCAE. PRO were assessed using validated Quality-of-Life and sexual questionnaires. Statistical analysis included Generalized-Linear-Mixed-Models and Spearman's rho-correlation coefficients. Results: 113 eligible patients were included. Mostly mild (grade 1) vaginal changes were reported over time in about 20% (range 11–37%). At 2-years, 47% was not sexually active. Approximately 50% of the sexually active women reported any vaginal and sexual functioning problems and distress over time; more substantial vaginal and sexual problems and distress were reported by up to 14%, 20% and 8%, respectively. Physician-assessed vaginal changes and PRO sexual satisfaction differed significantly (p ≤ .05) between baseline and first follow-up, without further significant changes over time. No or only small associations between physician-assessed vaginal changes and PRO vaginal functioning problems and sexual distress were found. Conclusions: Mild vaginal changes were reported after image-guided radio(chemo)therapy and brachytherapy, potentially due to the combination of tumors with limited vaginal involvement, EMBRACE-specific treatment optimization and rehabilitation recommendations. Although vaginal and sexual functioning problems and sexual distress were frequently reported, the rate of substantial problems and distress was low. The lack of association between vaginal changes, vaginal functioning problems and sexual distress shows that sexual functioning is more complex than vaginal morbidity alone.

Published
2023
Full Text
View/download PDF

3. Tumoren van de vrouwelijke geslachtsorganen

Author

Trimbos, J. B. M. Z., Kruitwagen, R. F. P. M., Smit, V. T. H. B. M., Creutzberg, C. L., van de Velde, C.J.H., editor, van der Graaf, W.T.A., editor, van Krieken, J.H.J.M., editor, and Marijnen, C.A.M., editor

Published
2017
Full Text
View/download PDF

4. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

Author

Wortman, B. G., Creutzberg, C. L., Putter, H., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen-Banasik, E. M., Mens, J. W. M., Slot, A., Kroese, M. C. Stenfert, van Triest, B., Nijman, H. W., Stelloo, E., Bosse, T., de Boer, S. M., van Putten, W. L. J., Smit, V. T. H. B. M, Nout, R. A., and for the PORTEC Study Group

Published
2018
Full Text
View/download PDF

6. Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity substudy

Author

MS Radiotherapie, Cancer, Suvaal, I, Kirchheiner, K, Nout, R A, Sturdza, A E, Van Limbergen, E, Lindegaard, J C, Putter, H, Jürgenliemk-Schulz, I M, Chargari, C, Tanderup, K, Pötter, R, Creutzberg, C L, Ter Kuile, M M, MS Radiotherapie, Cancer, Suvaal, I, Kirchheiner, K, Nout, R A, Sturdza, A E, Van Limbergen, E, Lindegaard, J C, Putter, H, Jürgenliemk-Schulz, I M, Chargari, C, Tanderup, K, Pötter, R, Creutzberg, C L, and Ter Kuile, M M

Published
2023

9. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)

Author

Post, C. C.B., Westermann, A. M., Boere, I. A., Witteveen, P. O., Ottevanger, P. B., Sonke, G. S., Lalisang, R. I., Putter, H., Meershoek-Klein Kranenbarg, E., Braak, J. P.B.M., Creutzberg, C. L., Bosse, T., Kroep, J. R., Post, C. C.B., Westermann, A. M., Boere, I. A., Witteveen, P. O., Ottevanger, P. B., Sonke, G. S., Lalisang, R. I., Putter, H., Meershoek-Klein Kranenbarg, E., Braak, J. P.B.M., Creutzberg, C. L., Bosse, T., and Kroep, J. R.

Abstract

Background: Patients with advanced endometrial cancer have a poor prognosis, and treatment options are limited. The investigator-initiated, multicenter, phase II DOMEC trial (NCT03951415) is the first trial to report data on efficacy and safety of combined treatment with PD-L1 and PARP inhibition for advanced endometrial cancer. Patients and methods: Patients with metastatic or recurrent endometrial cancer were enrolled. Patients received durvalumab 1500 mg intravenously q4w and olaparib 300 mg 2dd until disease progression, unacceptable toxicity, or patient withdrawal. Patients with at least 4 weeks of treatment were evaluable for analysis. The primary endpoint was progression-free survival at 6 months. Evidence for efficacy was defined as progression-free survival at 6 months in ≥50% of patients. Secondary endpoints included safety, objective response and overall survival. Results: From July 2019, through November 2020, 55 patients were enrolled. At data cut-off (September 2021), 4 of the 50 evaluable patients were still on treatment. Seventeen patients (34%) were progression-free at 6 months. Objective response rate was 16% (95% CI, 8.3 to 28.5) with 1 complete and 7 partial responses. With a median follow-up of 17.6 months, median progression-free survival was 3.4 months (95% CI, 2.8 to 6.2) and median overall survival was 8.0 months (95% CI, 7.5 to 14.3). Grade 3 treatment-related adverse events occurred in 8 patients (16%), predominantly anemia. There were no grade 4 or 5 treatment-related adverse events. Conclusion: The combination of durvalumab and olaparib was well tolerated, but did not meet the prespecified 50% 6-month progression-free survival in this heterogeneous patient population with advanced endometrial cancer.

Published
2022

10. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

Author

Oaknin, A, Bosse, T, Creutzberg, C, Giornelli, G, Harter, P, Joly, F, Lorusso, D, Marth, C, Makker, V, Mirza, M, Ledermann, J, Colombo, N, Oaknin A., Bosse T. J., Creutzberg C. L., Giornelli G., Harter P., Joly F., Lorusso D., Marth C., Makker V., Mirza M. R., Ledermann J. A., Colombo N., Oaknin, A, Bosse, T, Creutzberg, C, Giornelli, G, Harter, P, Joly, F, Lorusso, D, Marth, C, Makker, V, Mirza, M, Ledermann, J, Colombo, N, Oaknin A., Bosse T. J., Creutzberg C. L., Giornelli G., Harter P., Joly F., Lorusso D., Marth C., Makker V., Mirza M. R., Ledermann J. A., and Colombo N.

Published
2022

11. Microcystic elongated and fragmented (MELF) pattern of invasion:Molecular features and prognostic significance in the PORTEC-1 and -2 trials

Author

van den Heerik, A. S.V.M., Aiyer, K. T.S., Stelloo, E., Jürgenliemk-Schulz, I. M., Lutgens, L. C.H.W., Jobsen, J. J., Mens, J. W.M., van der Steen-Banasik, E. M., Creutzberg, C. L., Smit, V. T.H.B.M., Horeweg, N., Bosse, T., van den Heerik, A. S.V.M., Aiyer, K. T.S., Stelloo, E., Jürgenliemk-Schulz, I. M., Lutgens, L. C.H.W., Jobsen, J. J., Mens, J. W.M., van der Steen-Banasik, E. M., Creutzberg, C. L., Smit, V. T.H.B.M., Horeweg, N., and Bosse, T.

Abstract

Objective: Microcystic, elongated fragmented (MELF) pattern of myometrial invasion is a distinct histologic feature occasionally seen in low-grade endometrial carcinomas (EC). The prognostic relevance of MELF invasion was uncertain due to conflicting data, and it had not yet appropriately been studied in the context of the molecular EC classification. We aimed to determine the relation of MELF invasion with clinicopathological and molecular characteristics, and define its prognostic relevance in early-stage low/intermediate risk EC. Methods: Single whole tumor slides of 979 (85.8%) out of 1141 (high)intermediate-risk EC of women who participated in the PORTEC-1/−2 trials were available for review. Clinicopathological and molecular features were compared between MELF invasion positive and negative cases. Time-to-event analyses were done by Kaplan-Meier method, log-rank tests and Cox’ proportional hazards models. Results: MELF invasion was found in 128 (13.1%) cases, and associated with grade 1–2 histology, deep myometrial invasion and substantial lymph-vascular space invasion (LVSI). 85.6% of MELF invasion positive tumors were no-specific-molecular-profile (NSMP) EC. NSMP EC with MELF invasion were CTNNB1 wild type in 92.2% and KRAS mutated in 24.4% of cases. Risk of recurrence was lower for MELF invasion positive as compared to MELF invasion negative cases (4.9% vs. 12.7%, p = 0.026). However, MELF invasion had no independent impact on risk of recurrence (HR 0.65, p = 0.30) after correction for clinicopathological and molecular factors. Conclusions: MELF invasion has no independent impact on risk of recurrence in early-stage EC, and is frequently observed in low-grade NSMP tumors. Routine assessment of MELF invasion has no clinical implications and is not recommended.

Published
2022

12. p53 immunohistochemistry in endometrial cancer:clinical and molecular correlates in the PORTEC-3 trial

Author

Vermij, Lisa, Léon-Castillo, Alicia, Singh, Naveena, Powell, M. E., Edmondson, Richard J., Genestie, Catherine, Khaw, Pearly, Pyman, Jan, McLachlin, C. Meg, Ghatage, Prafull, de Boer, Stephanie M., Nijman, H. W., Smit, V. T.H.B.M., Crosbie, Emma J., Leary, Alexandra, Creutzberg, Carien L., Horeweg, Nanda, Bosse, Tjalling, de Boer, S. M., Creutzberg, C. L., Bosse, T., Kroep, J., Nout, R. A., de Bruyn, M., Singh, N., Kitchener, H. C., Crosbie, E., Edmondson, R., Church, D. N., Leary, A., Mileshkin, L., Pollock, P. M., MacKay, H., Vermij, Lisa, Léon-Castillo, Alicia, Singh, Naveena, Powell, M. E., Edmondson, Richard J., Genestie, Catherine, Khaw, Pearly, Pyman, Jan, McLachlin, C. Meg, Ghatage, Prafull, de Boer, Stephanie M., Nijman, H. W., Smit, V. T.H.B.M., Crosbie, Emma J., Leary, Alexandra, Creutzberg, Carien L., Horeweg, Nanda, Bosse, Tjalling, de Boer, S. M., Creutzberg, C. L., Bosse, T., Kroep, J., Nout, R. A., de Bruyn, M., Singh, N., Kitchener, H. C., Crosbie, E., Edmondson, R., Church, D. N., Leary, A., Mileshkin, L., Pollock, P. M., and MacKay, H.

Abstract

Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO and identifies p53-abnormal (p53abn) EC as the subgroup with the poorest prognosis and the most likely to benefit from adjuvant chemo(radio)therapy. P53abn EC are POLE wildtype, mismatch repair proficient and show abnormal immunohistochemical (IHC) staining for p53. Correct interpretation of routinely performed p53 IHC has therefore become of paramount importance. We aimed to comprehensively investigate abnormal p53 IHC patterns and their relation to clinicopathological and molecular features. Tumor material of 411 molecularly classified high-risk EC from consenting patients from the PORTEC-3 clinical trial were collected. p53 IHC was successful in 408 EC and was considered abnormal when the tumor showed a mutant expression pattern (including subclonal): overexpression, null or cytoplasmic. The presence of pathogenic mutations was determined by next generation sequencing (NGS). Abnormal p53 expression was observed in 131/408 (32%) tumors. The most common abnormal p53 IHC pattern was overexpression (n = 89, 68%), followed by null (n = 12, 9%) and cytoplasmic (n = 3, 2%). Subclonal abnormal p53 staining was observed in 27 cases (21%), which was frequently but not exclusively, associated with POLE mutations and/or MMRd (n = 22/27; p < 0.001). Agreement between p53 IHC and TP53 NGS was observed in 90.7%, resulting in a sensitivity and specificity of 83.6% and 94.3%, respectively. Excluding POLEmut and MMRd EC, as per the WHO-endorsed algorithm, increased the accuracy to 94.5% with sensitivity and specificity of 95.0% and 94.1%, respectively. Our data shows that awareness of the abnormal p53 IHC patterns are prerequisites for correct EC molecular classification. Subclonal abnormal p53 expression is a strong indicator for POLEmut and/or MMRd EC. No significant differences in clinical outcomes were observed among the abnormal p53 IHC patterns. Our data support use of the WHO-endo

Published
2022

13. Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials

Author

MS Radiotherapie, Cancer, van den Heerik, A. S.V.M., Aiyer, K. T.S., Stelloo, E., Jürgenliemk-Schulz, I. M., Lutgens, L. C.H.W., Jobsen, J. J., Mens, J. W.M., van der Steen-Banasik, E. M., Creutzberg, C. L., Smit, V. T.H.B.M., Horeweg, N., Bosse, T., MS Radiotherapie, Cancer, van den Heerik, A. S.V.M., Aiyer, K. T.S., Stelloo, E., Jürgenliemk-Schulz, I. M., Lutgens, L. C.H.W., Jobsen, J. J., Mens, J. W.M., van der Steen-Banasik, E. M., Creutzberg, C. L., Smit, V. T.H.B.M., Horeweg, N., and Bosse, T.

Published
2022

14. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)

Author

MS Radiotherapie, MS Medische Oncologie, Cancer, Post, C C B, Westermann, A M, Boere, I A, Witteveen, P O, Ottevanger, P B, Sonke, G S, Lalisang, R I, Putter, H, Meershoek-Klein Kranenbarg, E, Braak, J P B M, Creutzberg, C L, Bosse, T, Kroep, J R, MS Radiotherapie, MS Medische Oncologie, Cancer, Post, C C B, Westermann, A M, Boere, I A, Witteveen, P O, Ottevanger, P B, Sonke, G S, Lalisang, R I, Putter, H, Meershoek-Klein Kranenbarg, E, Braak, J P B M, Creutzberg, C L, Bosse, T, and Kroep, J R

Published
2022

18. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Author

Concin, N, Matias-Guiu, X, Vergote, I, Cibula, D, Mirza, M, Marnitz, S, Ledermann, J, Bosse, T, Chargari, C, Fagotti, A, Fotopoulou, C, Gonzalez Martin, A, Lax, S, Lorusso, D, Marth, C, Morice, P, Nout, R, O'Donnell, D, Querleu, D, Raspollini, M, Sehouli, J, Sturdza, A, Taylor, A, Westermann, A, Wimberger, P, Colombo, N, Planchamp, F, Creutzberg, C, Concin N., Matias-Guiu X., Vergote I., Cibula D., Mirza M. R., Marnitz S., Ledermann J., Bosse T., Chargari C., Fagotti A., Fotopoulou C., Gonzalez Martin A., Lax S., Lorusso D., Marth C., Morice P., Nout R. A., O'Donnell D., Querleu D., Raspollini M. R., Sehouli J., Sturdza A., Taylor A., Westermann A., Wimberger P., Colombo N., Planchamp F., Creutzberg C. L., Concin, N, Matias-Guiu, X, Vergote, I, Cibula, D, Mirza, M, Marnitz, S, Ledermann, J, Bosse, T, Chargari, C, Fagotti, A, Fotopoulou, C, Gonzalez Martin, A, Lax, S, Lorusso, D, Marth, C, Morice, P, Nout, R, O'Donnell, D, Querleu, D, Raspollini, M, Sehouli, J, Sturdza, A, Taylor, A, Westermann, A, Wimberger, P, Colombo, N, Planchamp, F, Creutzberg, C, Concin N., Matias-Guiu X., Vergote I., Cibula D., Mirza M. R., Marnitz S., Ledermann J., Bosse T., Chargari C., Fagotti A., Fotopoulou C., Gonzalez Martin A., Lax S., Lorusso D., Marth C., Morice P., Nout R. A., O'Donnell D., Querleu D., Raspollini M. R., Sehouli J., Sturdza A., Taylor A., Westermann A., Wimberger P., Colombo N., Planchamp F., and Creutzberg C. L.

Abstract

A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide.

Published
2021

19. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Author

Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, Anna, Fotopoulou, C., Gonzalez Martin, A., Lax, S., Lorusso, Domenica, Marth, C., Morice, P., Nout, R. A., O'Donnell, D., Querleu, D., Raspollini, M. R., Sehouli, J., Sturdza, A., Taylor, Anita, Westermann, A., Wimberger, P., Colombo, N., Planchamp, F., Creutzberg, C. L., Fagotti A. (ORCID:0000-0001-5579-335X), Lorusso D., Taylor A., Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, Anna, Fotopoulou, C., Gonzalez Martin, A., Lax, S., Lorusso, Domenica, Marth, C., Morice, P., Nout, R. A., O'Donnell, D., Querleu, D., Raspollini, M. R., Sehouli, J., Sturdza, A., Taylor, Anita, Westermann, A., Wimberger, P., Colombo, N., Planchamp, F., Creutzberg, C. L., Fagotti A. (ORCID:0000-0001-5579-335X), Lorusso D., and Taylor A.

Abstract

A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide.

Published
2021

21. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy

Author

Creutzberg, C. L., Leon-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., Leary, A., Nijman, H. W., Singh, N., Pollock, P., Fyles, A., Haie-Meder, C., Smit, V. T. H. B. M., Edmondson, R. J., Putter, H., Kitchener, H. C., Crosbie, E. J., de Bruyn, M., Nout, R., Bosse, T., Targeted Gynaecologic Oncology (TARGON), and Translational Immunology Groningen (TRIGR)

Published
2019

22. Implementing clinical practice guidelines: time to assess it

Author

Sessa, C, Colombo, N, Creutzberg, C, Concin, N, Wimberger, P, Curigliano, G, Marinoni, K, Douillard, J, Pentheroudakis, G, Torri, V, Rauh, S, Sessa C., Colombo N., Creutzberg C. L., Concin N., Wimberger P., Curigliano G., Marinoni K., Douillard J. -Y., Pentheroudakis G., Torri V., Rauh S., Sessa, C, Colombo, N, Creutzberg, C, Concin, N, Wimberger, P, Curigliano, G, Marinoni, K, Douillard, J, Pentheroudakis, G, Torri, V, Rauh, S, Sessa C., Colombo N., Creutzberg C. L., Concin N., Wimberger P., Curigliano G., Marinoni K., Douillard J. -Y., Pentheroudakis G., Torri V., and Rauh S.

Published
2020

23. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Author

de Boer, S, Powell, M, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, Ottevanger, P, Ledermann, J, Khaw, P, D'Amico, R, Fyles, A, Baron, M, Jurgenliemk-Schulz, I, Kitchener, H, Nijman, H, Wilson, G, Brooks, S, Gribaudo, S, Provencher, D, Hanzen, C, Kruitwagen, R, Smit, V, Singh, N, Do, V, Lissoni, A, Nout, R, Feeney, A, Verhoeven-Adema, K, Putter, H, Creutzberg, C, Mccormack, M, Whitmarsh, K, Allerton, R, Gregory, D, Symonds, P, Hoskin, P, Adusumalli, M, Anand, A, Wade, R, Stewart, A, Taylor, W, Lutgens, L, Hollema, H, Pras, E, Snyers, A, Westerveld, G, Jobsen, J, Slot, A, Mens, J, Stam, T, Van Triest, B, Van der Steen-Banasik, E, De Winter, K, Quinn, M, Kolodziej, I, Pyman, J, Johnson, C, Capp, A, Fossati, R, Colombo, A, Carinelli, S, Ferrero, A, Artioli, G, Davidson, C, Mclachlin, C, Ghatage, P, Rittenberg, P, Souhami, L, Thomas, G, Duvillard, P, Berton-Rigaud, D, Tubiana-Mathieu, N, de Boer S. M., Powell M. E., Mileshkin L., Katsaros D., Bessette P., Haie-Meder C., Ottevanger P. B., Ledermann J. A., Khaw P., D'Amico R., Fyles A., Baron M. -H., Jurgenliemk-Schulz I. M., Kitchener H. C., Nijman H. W., Wilson G., Brooks S., Gribaudo S., Provencher D., Hanzen C., Kruitwagen R. F., Smit V. T. H. B. M., Singh N., Do V., Lissoni A., Nout R. A., Feeney A., Verhoeven-Adema K. W., Putter H., Creutzberg C. L., McCormack M., Whitmarsh K., Allerton R., Gregory D., Symonds P., Hoskin P. J., Adusumalli M., Anand A., Wade R., Stewart A., Taylor W., Lutgens L. C. H. W., Hollema H., Pras E., Snyers A., Westerveld G. H., Jobsen J. J., Slot A., Mens J. M., Stam T. C., Van Triest B., Van der Steen-Banasik E. M., De Winter K. A. J., Quinn M. A., Kolodziej I., Pyman J., Johnson C., Capp A., Fossati R., Colombo A., Carinelli S., Ferrero A., Artioli G., Davidson C., McLachlin C. M., Ghatage P., Rittenberg P. V. C., Souhami L., Thomas G., Duvillard P., Berton-Rigaud D., Tubiana-Mathieu N., de Boer, S, Powell, M, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, Ottevanger, P, Ledermann, J, Khaw, P, D'Amico, R, Fyles, A, Baron, M, Jurgenliemk-Schulz, I, Kitchener, H, Nijman, H, Wilson, G, Brooks, S, Gribaudo, S, Provencher, D, Hanzen, C, Kruitwagen, R, Smit, V, Singh, N, Do, V, Lissoni, A, Nout, R, Feeney, A, Verhoeven-Adema, K, Putter, H, Creutzberg, C, Mccormack, M, Whitmarsh, K, Allerton, R, Gregory, D, Symonds, P, Hoskin, P, Adusumalli, M, Anand, A, Wade, R, Stewart, A, Taylor, W, Lutgens, L, Hollema, H, Pras, E, Snyers, A, Westerveld, G, Jobsen, J, Slot, A, Mens, J, Stam, T, Van Triest, B, Van der Steen-Banasik, E, De Winter, K, Quinn, M, Kolodziej, I, Pyman, J, Johnson, C, Capp, A, Fossati, R, Colombo, A, Carinelli, S, Ferrero, A, Artioli, G, Davidson, C, Mclachlin, C, Ghatage, P, Rittenberg, P, Souhami, L, Thomas, G, Duvillard, P, Berton-Rigaud, D, Tubiana-Mathieu, N, de Boer S. M., Powell M. E., Mileshkin L., Katsaros D., Bessette P., Haie-Meder C., Ottevanger P. B., Ledermann J. A., Khaw P., D'Amico R., Fyles A., Baron M. -H., Jurgenliemk-Schulz I. M., Kitchener H. C., Nijman H. W., Wilson G., Brooks S., Gribaudo S., Provencher D., Hanzen C., Kruitwagen R. F., Smit V. T. H. B. M., Singh N., Do V., Lissoni A., Nout R. A., Feeney A., Verhoeven-Adema K. W., Putter H., Creutzberg C. L., McCormack M., Whitmarsh K., Allerton R., Gregory D., Symonds P., Hoskin P. J., Adusumalli M., Anand A., Wade R., Stewart A., Taylor W., Lutgens L. C. H. W., Hollema H., Pras E., Snyers A., Westerveld G. H., Jobsen J. J., Slot A., Mens J. M., Stam T. C., Van Triest B., Van der Steen-Banasik E. M., De Winter K. A. J., Quinn M. A., Kolodziej I., Pyman J., Johnson C., Capp A., Fossati R., Colombo A., Carinelli S., Ferrero A., Artioli G., Davidson C., McLachlin C. M., Ghatage P., Rittenberg P. V. C., Souhami L., Thomas G., Duvillard P., Berton-Rigaud D., and Tubiana-Mathieu N.

Abstract

Background: The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We updated the analysis to investigate patterns of recurrence and did a post-hoc survival analysis. Methods: In the multicentre randomised phase 3 PORTEC-3 trial, women with high-risk endometrial cancer were eligible if they had International Federation of Gynaecology and Obstetrics (FIGO) 2009 stage I, endometrioid grade 3 cancer with deep myometrial invasion or lymphovascular space invasion, or both; stage II or III disease; or stage I–III disease with serous or clear cell histology; were aged 18 years and older; and had a WHO performance status of 0–2. Participants were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or chemoradiotherapy (two cycles of cisplatin 50 mg/m2 given intravenously during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2 given intravenously), by use of a biased coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage, and histological type. The co-primary endpoints were overall survival and failure-free survival. Secondary endpoints of vaginal, pelvic, and distant recurrence were analysed according to the first site of recurrence. Survival endpoints were analysed by intention-to-treat, and adjusted for stratification factors. Competing risk methods were used for failure-free survival and recurrence. We did a post-hoc analysis to analyse patterns of recurrence with 1 additional year of follow-up. The study was closed on Dec 20, 2013; follow-up is ongoing. This study is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. Findings: Between Nov 23, 2006, and Dec 20, 2013, 686 women were enrolled, of whom 660 were eligible and evaluable (330 in the chemoradiotherapy group, and 330 in the rad

Published
2019

24. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Author

de Boer S. M., Powell M. E., Mileshkin L., Katsaros D., Bessette P., Haie-Meder C., Ottevanger P. B., Ledermann J. A., Khaw P., Colombo A., Fyles A., Baron M. -H., Jurgenliemk-Schulz I. M., Kitchener H. C., Nijman H. W., Wilson G., Brooks S., Carinelli S., Provencher D., Hanzen C., Lutgens L. C. H. W., Smit V. T. H. B. M., Singh N., Do V., D'Amico R., Nout R. A., Feeney A., Verhoeven-Adema K. W., Putter H., Creutzberg C. L., McCormack M., Whitmarsh K., Allerton R., Gregory D., Symonds P., Hoskin P. J., Adusumalli M., Anand A., Wade R., Stewart A., Taylor W., Kruitwagen R. F. P. M., Hollema H., Pras E., Snyers A., Stalpers L., Jobsen J. J., Slot A., Mens J. -W. M., Stam T. C., Van Triest B., Van der Steen - Banasik E. M., De Winter K. A. J., Quinn M. A., Kolodziej I., Pyman J., Johnson C., Capp A., Fossati R., Gribaudo S., Lissoni A. A., Ferrero A., Artioli G., Davidson C., McLachlin C. M., Ghatage P., Rittenberg P. V. C., Souhami L., Thomas G., Duvillard P., Berton-Rigaud D., Tubiana-Mathieu N., de Boer, S, Powell, M, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, Ottevanger, P, Ledermann, J, Khaw, P, Colombo, A, Fyles, A, Baron, M, Jurgenliemk-Schulz, I, Kitchener, H, Nijman, H, Wilson, G, Brooks, S, Carinelli, S, Provencher, D, Hanzen, C, Lutgens, L, Smit, V, Singh, N, Do, V, D'Amico, R, Nout, R, Feeney, A, Verhoeven-Adema, K, Putter, H, Creutzberg, C, Mccormack, M, Whitmarsh, K, Allerton, R, Gregory, D, Symonds, P, Hoskin, P, Adusumalli, M, Anand, A, Wade, R, Stewart, A, Taylor, W, Kruitwagen, R, Hollema, H, Pras, E, Snyers, A, Stalpers, L, Jobsen, J, Slot, A, Mens, J, Stam, T, Van Triest, B, Van der Steen - Banasik, E, De Winter, K, Quinn, M, Kolodziej, I, Pyman, J, Johnson, C, Capp, A, Fossati, R, Gribaudo, S, Lissoni, A, Ferrero, A, Artioli, G, Davidson, C, Mclachlin, C, Ghatage, P, Rittenberg, P, Souhami, L, Thomas, G, Duvillard, P, Berton-Rigaud, D, and Tubiana-Mathieu, N

Subjects
Canada, Antineoplastic Combined Chemotherapy Protocol, Paclitaxel, Time Factor, Risk Factor, Australia, Chemoradiotherapy, Adjuvant, Middle Aged, Carboplatin, Europe, Treatment Outcome, Gynecologic Surgical Procedures, Lymph Node Excision, Endometrial Neoplasm, Female, Radiotherapy, Adjuvant, Dose Fractionation, Radiation, Cisplatin, Neoplasm Grading, Carcinoma, Endometrioid, Aged, Human, Neoplasm Staging, New Zealand
Abstract

Background: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. Methods: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup. Eligible women had high-risk endometrial cancer with FIGO 2009 stage I, endometrioid-type grade 3 with deep myometrial invasion or lymph-vascular space invasion (or both), endometrioid-type stage II or III, or stage I to III with serous or clear cell histology. Women were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or radiotherapy and chemotherapy (consisting of two cycles of cisplatin 50 mg/m2 given during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2) using a biased-coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage of cancer, and histological type. The co-primary endpoints were overall survival and failure-free survival. We used the Kaplan-Meier method, log-rank test, and Cox regression analysis for final analysis by intention to treat and adjusted for stratification factors. The study was closed on Dec 20, 2013, after achieving complete accrual; follow-up is ongoing. PORTEC-3 is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. Results: 686 women were enrolled between Nov 23, 2006, and Dec 20, 2013. 660 eligible patients were included in the final analysis, of whom 330 were assigned to chemoradiotherapy and 330 were assigned to radiotherapy. Median follow-up was 60·2 months (IQR 48·1–73·1). 5-year overall survival was 81·8% (95% CI 77·5–86·2) with chemoradiotherapy versus 76·7% (72·1–81·6) with radiotherapy (adjusted hazard ratio [HR] 0·76, 95% CI 0·54–1·06; p=0·11); 5-year failure-free survival was 75·5% (95% CI 70·3–79·9) versus 68·6% (63·1–73·4; HR 0·71, 95% CI 0·53–0·95; p=0·022). Grade 3 or worse adverse events during treatment occurred in 198 (60%) of 330 who received chemoradiotherapy versus 41 (12%) of 330 patients who received radiotherapy (p

Published
2018

25. Corrigendum to 'Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification' (Eur J Cancer (2017) 78 (82–90) (S0959804917308286) (10.1016/j.ejca.2017.03.010))

Author

Eggink, F. A., Mom, C. H., Bouwman, K., Boll, D., Becker, J. H., Creutzberg, C. L., Niemeijer, G. C., van Driel, W. J., Reyners, A. K., van der Zee, A. G., Bremer, G. L., Ezendam, N. P., Kruitwagen, R. F., Pijnenborg, J. M., Hollema, H., Nijman, H. W., van der Aa, M. A., Amsterdam Reproduction & Development (AR&D), CCA - Cancer Treatment and quality of life, and Obstetrics and gynaecology

Abstract

The authors regret that reference 5 (Milam et al., 2011) in the original article was included in the reference list incorrectly, and it should not have been included. The authors apologise for any inconvenience caused.

Published
2017
Full Text
View/download PDF

26. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Author

de Boer, S, Powell, M, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, Ottevanger, P, Ledermann, J, Khaw, P, Colombo, A, Fyles, A, Baron, M, Jurgenliemk-Schulz, I, Kitchener, H, Nijman, H, Wilson, G, Brooks, S, Carinelli, S, Provencher, D, Hanzen, C, Lutgens, L, Smit, V, Singh, N, Do, V, D'Amico, R, Nout, R, Feeney, A, Verhoeven-Adema, K, Putter, H, Creutzberg, C, Mccormack, M, Whitmarsh, K, Allerton, R, Gregory, D, Symonds, P, Hoskin, P, Adusumalli, M, Anand, A, Wade, R, Stewart, A, Taylor, W, Kruitwagen, R, Hollema, H, Pras, E, Snyers, A, Stalpers, L, Jobsen, J, Slot, A, Mens, J, Stam, T, Van Triest, B, Van der Steen - Banasik, E, De Winter, K, Quinn, M, Kolodziej, I, Pyman, J, Johnson, C, Capp, A, Fossati, R, Gribaudo, S, Lissoni, A, Ferrero, A, Artioli, G, Davidson, C, Mclachlin, C, Ghatage, P, Rittenberg, P, Souhami, L, Thomas, G, Duvillard, P, Berton-Rigaud, D, Tubiana-Mathieu, N, de Boer S. M., Powell M. E., Mileshkin L., Katsaros D., Bessette P., Haie-Meder C., Ottevanger P. B., Ledermann J. A., Khaw P., Colombo A., Fyles A., Baron M. -H., Jurgenliemk-Schulz I. M., Kitchener H. C., Nijman H. W., Wilson G., Brooks S., Carinelli S., Provencher D., Hanzen C., Lutgens L. C. H. W., Smit V. T. H. B. M., Singh N., Do V., D'Amico R., Nout R. A., Feeney A., Verhoeven-Adema K. W., Putter H., Creutzberg C. L., McCormack M., Whitmarsh K., Allerton R., Gregory D., Symonds P., Hoskin P. J., Adusumalli M., Anand A., Wade R., Stewart A., Taylor W., Kruitwagen R. F. P. M., Hollema H., Pras E., Snyers A., Stalpers L., Jobsen J. J., Slot A., Mens J. -W. M., Stam T. C., Van Triest B., Van der Steen - Banasik E. M., De Winter K. A. J., Quinn M. A., Kolodziej I., Pyman J., Johnson C., Capp A., Fossati R., Gribaudo S., Lissoni A. A., Ferrero A., Artioli G., Davidson C., McLachlin C. M., Ghatage P., Rittenberg P. V. C., Souhami L., Thomas G., Duvillard P., Berton-Rigaud D., Tubiana-Mathieu N., de Boer, S, Powell, M, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, Ottevanger, P, Ledermann, J, Khaw, P, Colombo, A, Fyles, A, Baron, M, Jurgenliemk-Schulz, I, Kitchener, H, Nijman, H, Wilson, G, Brooks, S, Carinelli, S, Provencher, D, Hanzen, C, Lutgens, L, Smit, V, Singh, N, Do, V, D'Amico, R, Nout, R, Feeney, A, Verhoeven-Adema, K, Putter, H, Creutzberg, C, Mccormack, M, Whitmarsh, K, Allerton, R, Gregory, D, Symonds, P, Hoskin, P, Adusumalli, M, Anand, A, Wade, R, Stewart, A, Taylor, W, Kruitwagen, R, Hollema, H, Pras, E, Snyers, A, Stalpers, L, Jobsen, J, Slot, A, Mens, J, Stam, T, Van Triest, B, Van der Steen - Banasik, E, De Winter, K, Quinn, M, Kolodziej, I, Pyman, J, Johnson, C, Capp, A, Fossati, R, Gribaudo, S, Lissoni, A, Ferrero, A, Artioli, G, Davidson, C, Mclachlin, C, Ghatage, P, Rittenberg, P, Souhami, L, Thomas, G, Duvillard, P, Berton-Rigaud, D, Tubiana-Mathieu, N, de Boer S. M., Powell M. E., Mileshkin L., Katsaros D., Bessette P., Haie-Meder C., Ottevanger P. B., Ledermann J. A., Khaw P., Colombo A., Fyles A., Baron M. -H., Jurgenliemk-Schulz I. M., Kitchener H. C., Nijman H. W., Wilson G., Brooks S., Carinelli S., Provencher D., Hanzen C., Lutgens L. C. H. W., Smit V. T. H. B. M., Singh N., Do V., D'Amico R., Nout R. A., Feeney A., Verhoeven-Adema K. W., Putter H., Creutzberg C. L., McCormack M., Whitmarsh K., Allerton R., Gregory D., Symonds P., Hoskin P. J., Adusumalli M., Anand A., Wade R., Stewart A., Taylor W., Kruitwagen R. F. P. M., Hollema H., Pras E., Snyers A., Stalpers L., Jobsen J. J., Slot A., Mens J. -W. M., Stam T. C., Van Triest B., Van der Steen - Banasik E. M., De Winter K. A. J., Quinn M. A., Kolodziej I., Pyman J., Johnson C., Capp A., Fossati R., Gribaudo S., Lissoni A. A., Ferrero A., Artioli G., Davidson C., McLachlin C. M., Ghatage P., Rittenberg P. V. C., Souhami L., Thomas G., Duvillard P., Berton-Rigaud D., and Tubiana-Mathieu N.

Abstract

Background: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. Methods: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup. Eligible women had high-risk endometrial cancer with FIGO 2009 stage I, endometrioid-type grade 3 with deep myometrial invasion or lymph-vascular space invasion (or both), endometrioid-type stage II or III, or stage I to III with serous or clear cell histology. Women were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or radiotherapy and chemotherapy (consisting of two cycles of cisplatin 50 mg/m2 given during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2) using a biased-coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage of cancer, and histological type. The co-primary endpoints were overall survival and failure-free survival. We used the Kaplan-Meier method, log-rank test, and Cox regression analysis for final analysis by intention to treat and adjusted for stratification factors. The study was closed on Dec 20, 2013, after achieving complete accrual; follow-up is ongoing. PORTEC-3 is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. Results: 686 women were enrolled between Nov 23, 2006, and Dec 20, 2013. 660 eligible patients were included in the final analysis, of whom 330 were assigned to chemoradiotherapy and 330 were assigned to radiotherapy. Median follow-up was 60·2 months (IQR 48·1–73·1). 5-year overall survival was 81·8% (95% CI

Published
2018

27. Unfavorable prognosis for low risk endometrial cancer patients with a discordant pre-versus postoperative risk stratification

Author

Eggink, F. A., Mom, C. H., Bouwman, K., Boll, D., Becker, J., Creutzberg, C. L., Niemeijer, G. C., van Driel, W. J., Reyners, A., van der Zee, A. G., Bremer, G. L., Ezendam, N. P., Kruitwagen, R. F., Pijnenborg, J. M., Hollema, H., Nijman, H. W., van der Aa, M. A., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON), and Translational Immunology Groningen (TRIGR)

Published
2016

28. RELATION BETWEEN PATIENT AND PHYSICIAN REPORTED TOXICITY IN THE RANDOMISED PORTEC-3 TRIAL OF RADIATION THERAPY (RT) WITH OR WITHOUT CHEMOTHERAPY FOR ENDOMETRIAL CANCER

Author

Stephanie M. de Boer, Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Nout, R. A., Kitchener, H. C., Ottevanger, P. B., Khaw, P., Colombo, A., Fyles, A., Baron, M. H., Nijman, H. W., Kruitwagen, R., Ledermann, J., Verhoeven-Adema, K. W., Smit, V. T., Putter, H., and Creutzberg, C. L.

Published
2015

31. Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre-versus post-operative risk stratification

Author

Eggink, F. A., Mom, C. H., Bouwman, K., Boll, D., Becker, J. H., Creutzberg, C. L., Niemeijer, G. C., van Driel, W. J., Reyners, A. K., van der Zee, A. G., Bremer, G. L., Ezendam, N. P., Kruitwagen, R. F., Pijnenborg, J. M., Hollema, H., Nijman, H. W., van der Aa, M. A., Eggink, F. A., Mom, C. H., Bouwman, K., Boll, D., Becker, J. H., Creutzberg, C. L., Niemeijer, G. C., van Driel, W. J., Reyners, A. K., van der Zee, A. G., Bremer, G. L., Ezendam, N. P., Kruitwagen, R. F., Pijnenborg, J. M., Hollema, H., Nijman, H. W., and van der Aa, M. A.

Abstract

Background: Pre-operative risk stratification based on endometrial sampling determines the extent of surgery for endometrial cancer (EC). We investigated the concordance of pre- and post-operative risk stratifications and the impact of discordance on survival.Methods: Patients diagnosed with EC within the first 6 months of the years 2005-2014 were selected from the Netherlands Cancer Registry (N = 7875). Pre-and post-operative risk stratifications were determined based on grade and/or histological subtype for 3784 eligible patients.Results: A discordant risk stratification was found in 10% of patients: 4% (N = 155) had high pre-and low post-operative risk and 6% (N = 215) had low pre-and high post-operative risk. Overall survival of patients with high pre-and low post-operative risk was less favourable compared to those with a concordant low risk (80% versus 89%, p = 0.002). This difference remained significant when correcting for age, stage, surgical staging and adjuvant therapy (hazard ratio 1.80, 95% confidence interval 1.28-2.53, p = 0.001). Survival of patients with low pre-and high post-operative risk did not differ from those with a concordant high risk (64% versus 62%, p = 0.295).Conclusion: Patients with high pre-and low post-operative risk have a less favourable prognosis compared to patients with a concordant low risk. Pre-operative risk stratifications contain independent prognostic information and should be incorporated into clinical decision-making. (C) 2017 Elsevier Ltd. All rights reserved.

Published
2017

32. Corrigendum to 'Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification' (vol 78, pg 82, 2017)

Author

Eggink, F. A., Mom, C. H., Bouwman, K., Boll, D., Becker, J. H., Creutzberg, C. L., Niemeijer, G. C., van Driel, W. J., Reyners, A. K., van der Zee, A. G., Bremer, G. L., Ezendam, N. P., Kruitwagen, R. F., Pijnenborg, J. M., Hollema, H., Nijman, H. W., van der Aa, M. A., Eggink, F. A., Mom, C. H., Bouwman, K., Boll, D., Becker, J. H., Creutzberg, C. L., Niemeijer, G. C., van Driel, W. J., Reyners, A. K., van der Zee, A. G., Bremer, G. L., Ezendam, N. P., Kruitwagen, R. F., Pijnenborg, J. M., Hollema, H., Nijman, H. W., and van der Aa, M. A.

Published
2017

34. A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer

Author

Bakker, R. M., primary, Mens, J. W. M., additional, de Groot, H. E., additional, Tuijnman-Raasveld, C. C., additional, Braat, C., additional, Hompus, W. C. P., additional, Poelman, J. G. M., additional, Laman, M. S., additional, Velema, L. A., additional, de Kroon, C. D., additional, van Doorn, H. C., additional, Creutzberg, C. L., additional, and ter Kuile, M. M., additional

Published
2016
Full Text
View/download PDF

36. Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters

Author

Versluis, M A, primary, de Jong, R A, additional, Plat, A, additional, Bosse, T, additional, Smit, V T, additional, Mackay, H, additional, Powell, M, additional, Leary, A, additional, Mileshkin, L, additional, Kitchener, H C, additional, Crosbie, E J, additional, Edmondson, R J, additional, Creutzberg, C L, additional, Hollema, H, additional, Daemen, T, additional, de Bock, G H, additional, and Nijman, H W, additional

Published
2015
Full Text
View/download PDF

38. Gynecologic cancer intergroup (GCIG) endometrial cancer clinical trials planning meeting: Taking endometrial cancer trials into the translational era

Author

Creutzberg, C, Kitchener, H, Birrer, M, Landoni, F, Lu, K, Powell, M, Aghajanian, C, Edmondson, R, Goodfellow, P, Quinn, M, Salvesen, H, Thomas, G, Creutzberg C. L., Kitchener H. C., Birrer M. J., Landoni F., Lu K. H., Powell M., Aghajanian C., Edmondson R., Goodfellow P. J., Quinn M., Salvesen H. B., Thomas G., Creutzberg, C, Kitchener, H, Birrer, M, Landoni, F, Lu, K, Powell, M, Aghajanian, C, Edmondson, R, Goodfellow, P, Quinn, M, Salvesen, H, Thomas, G, Creutzberg C. L., Kitchener H. C., Birrer M. J., Landoni F., Lu K. H., Powell M., Aghajanian C., Edmondson R., Goodfellow P. J., Quinn M., Salvesen H. B., and Thomas G.

Abstract

Objective: The second Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting was held on December 1, 2012, and included international multidisciplinary representatives of the 24 member groups. The aims were to review recent advances in molecular pathology of endometrial cancer, focusing on molecular-based therapy, and to identify key hypotheses and issues to be addressed through international collaborative clinical trials. Methods: Reviews and summaries of current knowledge were presented followed by parallelworking group sessions for surgery, adjuvant and systemic therapy, and translational research. Plenary discussions were held to integrate translational and clinical issues, and a final discussion session to agree on key trial concepts. Results and Conclusions: Proposals to take forward on the following trials were agreed: (1) lymphadenectomy to direct adjuvant treatment in women with high-risk endometrial cancer, including a sentinel node substudy; (2) conservative therapy for low-risk endometrial cancers in morbidly obese women with high surgical risks and for fertility-sparing treatment in premenopausal patients; (3) adjuvant therapy for women with early-stage carcinosarcoma. A proposal was made that a GCIG Early Phase Consortium be developed to serve as an international platform for rapid assessment of biomarkers. Copyright © 2013 by IGCS and ESGO.

Published
2013

50. Patterns of recurrence in the randomised PORTEC-3 trial of chemoradiotherapy for endometrial cancer

Author

De Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., Fyles, A., Baron, M. H., Jurgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Kolodziej, I., Carinelli, S., Lutgens, L. C. H. W., Smit, V. T. H. B. M., Singh, N., Nout, R. A., Verhoeven-Adema, K. W., Putter, H., Creutzberg, C. L., Targeted Gynaecologic Oncology (TARGON), and Translational Immunology Groningen (TRIGR)

Catalog

Books, media, physical & digital resources
See catalog results